Connect Biopharma Advances Rademikibart Trials with $20M Financing Boost

Event summary

  • Phase 2 Seabreeze STAT studies for asthma and COPD continue as planned following independent DMC review.
  • Topline data from both Phase 2 studies expected mid-2026.
  • $20.2 million private placement financing closed on March 31, 2026.
  • Cash and cash equivalents were $46.0 million as of March 31, 2026.

The big picture

Connect Biopharma is advancing its lead candidate, rademikibart, targeting IL-4Rα for inflammatory diseases like asthma and COPD. The company's recent financing and positive Phase 1 data for IV rademikibart highlight its strategic focus on addressing significant unmet needs in the hospital setting. The upcoming Phase 2 topline data and potential FDA alignment will be critical milestones in its path to commercialization.

What we're watching

Clinical Trial Momentum
Whether the Phase 2 Seabreeze STAT studies will deliver positive topline data mid-2026 as planned, which is critical for advancing to Phase 3 trials.
Regulatory Alignment
How Connect Biopharma will navigate FDA alignment on a Phase 3 program following topline data, which will be key for regulatory approval.
Financial Runway
The pace at which Connect Biopharma will utilize its $46.0 million in cash reserves, given its current operating plan and projections.